Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
BridgeBio, Helsinn Group enter strategic collaboration for GPX4 inhibitor » 07:36
11/19/21
11/19
07:36
11/19/21
07:36
BBIO

BridgeBio

$44.93 /

-1.2 (-2.60%)

BridgeBio Pharma and…

BridgeBio Pharma and Helsinn Group announced they have entered into a strategic collaboration to co-develop and co-commercialize a potentially first-in-class inhibitor designed to target glutathione peroxidase 4 with the hope of providing an effective new therapy for patients with difficult-to-treat tumors. The joint collaboration for BridgeBio's GPX4 inhibitor was established as part of a new non-exclusive collaboration framework between BridgeBio and Helsinn that allows the companies to propose co-development and co-commercialization opportunities for preclinical precision oncology programs Under the terms of the non-exclusive agreement, BridgeBio and Helsinn will have the option to collaborate on preclinical oncology programs that are identified from time to time by either party. The agreement is designed to magnify the ability of both companies to identify small oncology interventions that may have greater potential to help patients in combination with larger investigational therapies. For each program that the parties agree to pursue, they will share global development responsibilities under an agreed cost split. Helsinn will have exclusive manufacturing and commercial rights to the programs under the agreement, with BridgeBio receiving a profit share on U.S. sales and tiered royalties on ex-U.S. sales. The first program under the framework collaboration agreement that the parties will pursue is GPX4, a potentially first-in-class inhibitor that may be an effective new therapy for certain cancer patients. GPX4 is an enzyme that is often elevated in cancer tissue and associated with a worse prognosis for patients. GPX4 neutralizes toxic free radicals at the lipid membrane, protecting cells from death by ferroptosis. The GPX4 inhibitor is being developed to induce ferroptosis in cancer cells with the potential to impact approximately 500,000 patients in need of a therapeutic option. The safety and efficacy of GPX4 has not yet been established by any health authority world-wide. The non-exclusive framework agreement builds on an earlier global collaboration and licensing agreement that BridgeBio and Helsinn Group's affiliates, Helsinn Healthcare S.A. and Helsinn Therapeutics, Inc., entered into in March 2021. Under that agreement, Helsinn Therapeutics is jointly responsible for further development and commercialization activities for infigratinib, a small molecule kinase inhibitor of FGFR, in oncology and all other indications except for skeletal dysplasias in the United States and other regions, sharing profits and losses on an equal basis. This includes exclusive commercialization rights for infigratinib in Canada, where Health Canada recently approved TRUSELTIQ under the Notice of Compliance with Conditions policy, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement. Helsinn will fund the majority of ongoing and future research and development related to infigratinib in oncology in the foregoing territory. BridgeBio will be eligible for tiered royalties as a percentage of adjusted net sales, and potential payments totaling up to $2.45B in the aggregate. BridgeBio previously entered a strategic collaboration with LianBio for development and commercialization of infigratinib in oncology indications in China, Hong Kong and Macau.

ShowHide Related Items >><<
BBIO BridgeBio
$44.93 /

-1.2 (-2.60%)

BBIO BridgeBio
$44.93 /

-1.2 (-2.60%)

09/10/21 BofA
BridgeBio upgraded to Buy from Neutral at BofA
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/13/21 Oppenheimer
Prothena price target raised to $76 from $54 at Oppenheimer
05/20/21 UBS
BridgeBio initiated with a Buy at UBS
BBIO BridgeBio
$44.93 /

-1.2 (-2.60%)

  • 12
    Feb
Hot Stocks
BridgeBio secures up to $750M in non-dilutive debt financing » 07:34
11/18/21
11/18
07:34
11/18/21
07:34
BBIO

BridgeBio

$46.11 /

-1.21 (-2.56%)

BridgeBio Pharma…

BridgeBio Pharma announced that it has executed a definitive credit facility agreement with a syndicate of lenders for up to $750M in financing. This facility, combined with the Company's existing cash balance as of September 30, 2021, provides access to over $1.2B to advance the Company's pipeline programs, support commercialization efforts, and enable the Company to pursue strategic business development opportunities. As structured, this financing is expected to fully fund BridgeBio's portfolio of more than 30 drug development and discovery programs into 2024, independent of near-term milestone readouts. It is a significant achievement in BridgeBio's broader efforts to attract diverse sources of capital to fund life science innovation and is aligned with its long-term strategy of creating non-dilutive financing pathways that leverage portfolio readouts - in addition to cash balance on hand - to extend runway. This financing announcement follows BridgeBio's repurchase of approximately $150M in its own common stock under its 2021 Share Repurchase Program, completing about $385.6M of equity and capped call purchases in the aggregate since its initial public offering in 2019. In addition, today's financing replaces the Company's $100.0M debt facility with Hercules. Collectively, these transactions represent a strategic recapitalization of the Company ahead of upcoming clinical data readouts. Key features of the credit facility include: $450M funded on November 17, 2021; An additional $300.0 million to be funded at the Company's option following either positive topline results from Part A of its Phase 3 ATTRibute-CM trial of TTR stabilizer for transthyretin amyloid cardiomyopathy, which is expected by the end of the year, OR positive proof-of-concept data for various pipeline programs by year end 2022, with $100M available upon each proof-of-concept, for up to three pipeline programs; Fixed interest rate of 9%, with 3% eligible at the Company's discretion to be paid in kind and added to principal; Maturity date of November 17, 2026; Interest-only period for three years, which may be extended to four years upon success of the Part A readout; Substantial flexibility for future business development, M&A, share repurchases, and royalty transactions; No financial covenants.

ShowHide Related Items >><<
BBIO BridgeBio
$46.11 /

-1.21 (-2.56%)

BBIO BridgeBio
$46.11 /

-1.21 (-2.56%)

09/10/21 BofA
BridgeBio upgraded to Buy from Neutral at BofA
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/13/21 Oppenheimer
Prothena price target raised to $76 from $54 at Oppenheimer
05/20/21 UBS
BridgeBio initiated with a Buy at UBS
BBIO BridgeBio
$46.11 /

-1.21 (-2.56%)

  • 12
    Feb
Earnings
BridgeBio reports Q3 EPS ($1.06), consensus (90c) » 07:45
11/04/21
11/04
07:45
11/04/21
07:45
BBIO

BridgeBio

$50.02 /

-0.995 (-1.95%)

Reports Q3 revenue…

Reports Q3 revenue $2.34M, consensus $17.36M.

ShowHide Related Items >><<
BBIO BridgeBio
$50.02 /

-0.995 (-1.95%)

BBIO BridgeBio
$50.02 /

-0.995 (-1.95%)

09/10/21 BofA
BridgeBio upgraded to Buy from Neutral at BofA
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/13/21 Oppenheimer
Prothena price target raised to $76 from $54 at Oppenheimer
05/20/21 UBS
BridgeBio initiated with a Buy at UBS
BBIO BridgeBio
$50.02 /

-0.995 (-1.95%)

  • 12
    Feb
Hot Stocks
BridgeBio doses first patient in Phase 1/2 clinical trial of BBP-812 » 07:34
11/03/21
11/03
07:34
11/03/21
07:34
BBIO

BridgeBio

$51.05 /

-0.78 (-1.50%)

BridgeBio Pharma…

BridgeBio Pharma announced that the first patient has been dosed in CANaspire, its Phase 1/2 clinical trial of BBP-812, an investigational adeno-associated virus 9 gene therapy for the treatment of Canavan disease. Canavan disease is an ultra-rare and fatal disease that affects approximately 1,000 children in the United States and European Union. There are currently no approved therapies for the condition.

ShowHide Related Items >><<
BBIO BridgeBio
$51.05 /

-0.78 (-1.50%)

BBIO BridgeBio
$51.05 /

-0.78 (-1.50%)

09/10/21 BofA
BridgeBio upgraded to Buy from Neutral at BofA
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/13/21 Oppenheimer
Prothena price target raised to $76 from $54 at Oppenheimer
05/20/21 UBS
BridgeBio initiated with a Buy at UBS
BBIO BridgeBio
$51.05 /

-0.78 (-1.50%)

  • 12
    Feb
Over a month ago
Conference/Events
BridgeBio participates in a conference call with Jefferies » 12:50
10/19/21
10/19
12:50
10/19/21
12:50
BBIO

BridgeBio

$48.70 /

+1 (+2.10%)

Jefferies Healthcare…

Jefferies Healthcare Analyst Yang holds a conference call with management to discuss the Company's Acoramidis Program on October 19 at 1 pm. Webcast Link

ShowHide Related Items >><<
BBIO BridgeBio
$48.70 /

+1 (+2.10%)

BBIO BridgeBio
$48.70 /

+1 (+2.10%)

09/10/21 BofA
BridgeBio upgraded to Buy from Neutral at BofA
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/13/21 Oppenheimer
Prothena price target raised to $76 from $54 at Oppenheimer
05/20/21 UBS
BridgeBio initiated with a Buy at UBS
BBIO BridgeBio
$48.70 /

+1 (+2.10%)

  • 12
    Feb
Conference/Events
BridgeBio participates in a conference call with Jefferies » 04:55
10/19/21
10/19
04:55
10/19/21
04:55
BBIO

BridgeBio

$47.85 /

-0.14 (-0.29%)

Jefferies Healthcare…

Jefferies Healthcare Analyst Yang holds a conference call with management to discuss the Company's Acoramidis Program on October 19 at 1 pm. Webcast Link

ShowHide Related Items >><<
BBIO BridgeBio
$47.85 /

-0.14 (-0.29%)

BBIO BridgeBio
$47.85 /

-0.14 (-0.29%)

09/10/21 BofA
BridgeBio upgraded to Buy from Neutral at BofA
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/13/21 Oppenheimer
Prothena price target raised to $76 from $54 at Oppenheimer
05/20/21 UBS
BridgeBio initiated with a Buy at UBS
BBIO BridgeBio
$47.85 /

-0.14 (-0.29%)

  • 12
    Feb
Conference/Events
BridgeBio participates in a conference call with Jefferies » 14:10
10/18/21
10/18
14:10
10/18/21
14:10
BBIO

BridgeBio

$48.03 /

+0.04 (+0.08%)

Jefferies Healthcare…

Jefferies Healthcare Analyst Yang holds a conference call with management to discuss the Company's Acoramidis Program on October 19 at 1 pm. Webcast Link

ShowHide Related Items >><<
BBIO BridgeBio
$48.03 /

+0.04 (+0.08%)

BBIO BridgeBio
$48.03 /

+0.04 (+0.08%)

09/10/21 BofA
BridgeBio upgraded to Buy from Neutral at BofA
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/13/21 Oppenheimer
Prothena price target raised to $76 from $54 at Oppenheimer
05/20/21 UBS
BridgeBio initiated with a Buy at UBS
BBIO BridgeBio
$48.03 /

+0.04 (+0.08%)

  • 12
    Feb
Conference/Events
BridgeBio management to meet virtually with Mizuho » 04:55
10/18/21
10/18
04:55
10/18/21
04:55
BBIO

BridgeBio

$48.00 /

-1.38 (-2.79%)

Virtual Meeting to be…

Virtual Meeting to be held on October 18 hosted by Mizuho.

ShowHide Related Items >><<
BBIO BridgeBio
$48.00 /

-1.38 (-2.79%)

BBIO BridgeBio
$48.00 /

-1.38 (-2.79%)

09/10/21 BofA
BridgeBio upgraded to Buy from Neutral at BofA
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/13/21 Oppenheimer
Prothena price target raised to $76 from $54 at Oppenheimer
05/20/21 UBS
BridgeBio initiated with a Buy at UBS
BBIO BridgeBio
$48.00 /

-1.38 (-2.79%)

  • 12
    Feb
Conference/Events
BridgeBio to host virtual research and development day » 08:25
10/12/21
10/12
08:25
10/12/21
08:25
BBIO

BridgeBio

$46.62 /

+2.49 (+5.64%)

Virtual Research and…

Virtual Research and Development Day to be held on October 12 at 8:30 am. Webcast Link

ShowHide Related Items >><<
BBIO BridgeBio
$46.62 /

+2.49 (+5.64%)

BBIO BridgeBio
$46.62 /

+2.49 (+5.64%)

09/10/21 BofA
BridgeBio upgraded to Buy from Neutral at BofA
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/13/21 Oppenheimer
Prothena price target raised to $76 from $54 at Oppenheimer
05/20/21 UBS
BridgeBio initiated with a Buy at UBS
BBIO BridgeBio
$46.62 /

+2.49 (+5.64%)

  • 12
    Feb
Hot Stocks
BridgeBio, Unnatural Products announce research discovery collaboration » 08:08
10/12/21
10/12
08:08
10/12/21
08:08
BBIO

BridgeBio

$46.62 /

+2.49 (+5.64%)

Unnatural Products…

Unnatural Products announced a research collaboration and option agreement with Bridge BioPharma. By leveraging UNP's technology, which takes macrocyclic tool compounds and turns them into drugs, UNP and BridgeBio will generate drug-like macrocycles with the hopes of creating the capabilities to hit intracellular targets associated with rare fibrotic diseases and potential oncology applications. UNP and BridgeBio are working to turn initial chemical series from exciting academic tool compounds into promising therapeutics. The terms of the partnership were not disclosed.

ShowHide Related Items >><<
BBIO BridgeBio
$46.62 /

+2.49 (+5.64%)

BBIO BridgeBio
$46.62 /

+2.49 (+5.64%)

09/10/21 BofA
BridgeBio upgraded to Buy from Neutral at BofA
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/13/21 Oppenheimer
Prothena price target raised to $76 from $54 at Oppenheimer
05/20/21 UBS
BridgeBio initiated with a Buy at UBS
BBIO BridgeBio
$46.62 /

+2.49 (+5.64%)

  • 12
    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.